- Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
- A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
- Soligenix Announces Reverse Stock Split
- Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
- Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
- SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
- Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
- Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
- Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
More ▼
Key statistics
On Friday, Soligenix Inc (SNGX:NAQ) closed at 2.11, 5.50% above its 52-week low of 2.00, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.21 |
---|---|
High | 2.30 |
Low | 2.04 |
Bid | 2.06 |
Offer | 2.23 |
Previous close | 2.26 |
Average volume | 151.63k |
---|---|
Shares outstanding | 987.49k |
Free float | 986.83k |
P/E (TTM) | -- |
Market cap | 2.08m USD |
EPS (TTM) | -11.83 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.
More ▼